TrialCurveJCOG1113 (liver cirrhosis subgroup): reconstructed Kaplan–Meier curves
Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | Jpn J Clin Oncol. 2025 Mar 7;55(6):594–602. doi: 10.1093/jjco/hyaf035 |
|---|---|
| DOI | 10.1093/jjco/hyaf035 |
| Registry | — |
| Phase | — |
| Conditions | — |
| Interventions | — |
| Sponsor | — |
| Enrolment | — |
| Source licence | Figure published under CC BY 4.0 |
Overall survival
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: clinically diagnosed LC 17.6 months; Non-LC 13.6 months. Survival at 12 months: clinically diagnosed LC 80%; Non-LC 56%. Hazard ratio Non-LC vs clinically diagnosed LC 0.96 (95% CI 0.49–1.86).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| clinically diagnosed LC | 10 | 10 | 17.6 |
| Non-LC | 84 | 66 | 13.6 |
- Non-LC vs clinically diagnosed LC: reconstructed HR 0.96 (95% CI 0.49–1.86)
Landmark survival (reconstructed)
| Time | clinically diagnosed LC | Non-LC |
|---|---|---|
| 6 mo | 100.0% | 86.9% |
| 12 mo | 80.0% | 56.0% |
| 18 mo | 50.0% | 38.6% |
| 24 mo | 20.0% | 28.7% |
| 36 mo | 10.0% | 16.5% |
Overall survival — Non-liver cirrhosis group (per caption; GC n=45 + GS n=39)
From figure panel · curves cross-checked by two independent readings · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: GS 15.7 months; GC 13.4 months. Survival at 12 months: GS 56%; GC 53%. Hazard ratio GS vs GC 0.93 (95% CI 0.57–1.51).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| GS | 39 | 34 | 15.7 |
| GC | 45 | 33 | 13.4 |
- GS vs GC: reconstructed HR 0.93 (95% CI 0.57–1.51)
Landmark survival (reconstructed)
| Time | GS | GC |
|---|---|---|
| 6 mo | 87.2% | 84.4% |
| 12 mo | 56.4% | 53.3% |
| 18 mo | 40.5% | 36.8% |
| 24 mo | 26.7% | 30.4% |
| 36 mo | 17.3% | 13.0% |
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/jcog1113-liver-cirrhosis-subgroup-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/jcog1113-liver-cirrhosis-subgroup-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: Jpn J Clin Oncol. 2025 Mar 7;55(6):594–602. doi: 10.1093/jjco/hyaf035 doi:10.1093/jjco/hyaf035. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/jcog1113-liver-cirrhosis-subgroup
Report a problem with these data
Related trials
- JCOG0905: Disease-free survival; Disease-free survival (good responders); Overall survival; Overall
- ADIUVO: Overall survival; Recurrence-free survival
- CONFIRM: Overall survival; Progression-free survival
- Convalescent plasma for severe COVID-19 in cancer patients: Overall survival (secondary endpoint)
- GENERATE: Overall survival (planned interim analysis); Overall survival (updated analysis); Progress
- JCOG1306: Overall survival; Progression-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials